All In Biotech

Drug Trial Radar · NCT07414953

A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

A Phase Ib Study of the Safety, Efficacy, Pharmacokinetics, and Immunogenicity of HS-10504 Combined Therapy in Advanced Non-small Cell Lung Cancer Patients

Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Mar 30, 2026

Primary completion

Apr 30, 2027

Study completion Nov 30, 2028

Sponsor

Sponsor type
Industry
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-10504 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Conditions

  • Lung Cancer

Interventions

  • HS-10504Drug

    HS-10504 administered orally every day

  • SHR-A2009Drug

    SHR-A2009 administered intravenously

  • HS-20122Drug

    HS-20122 administered intravenously

  • HS-20117Drug

    HS-20117 administered intravenously

  • SHR-1826Drug

    SHR-1826 administered intravenously

  • SHR-A2102Drug

    SHR-A2102 administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RP2D for CombinationTime frame: Through the full duration of this trial, approximately 2 years
  2. ORRTime frame: Through the full duration of this trial, approximately 2 years
  3. TEAETime frame: Through the full duration of this trial, approximately 2 years
  4. TRAETime frame: Through the full duration of this trial, approximately 2 years
  5. SAETime frame: Through the full duration of this trial, approximately 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.